About: Centanafadine

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Centanafadine (INN) (former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical. It was developed as a treatment for attention-deficit hyperactivity disorder (ADHD) and inhibits the reuptake of norepinephrine, dopamine, and serotonin with a ratio of 1:6:14, respectively. In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance. In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine. As of January 2018, Otsuka's pipeline indicates it is in Phase III clinical trials.

Property	Value
dbo:abstract	Centanafadine (INN) (former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical. It was developed as a treatment for attention-deficit hyperactivity disorder (ADHD) and inhibits the reuptake of norepinephrine, dopamine, and serotonin with a ratio of 1:6:14, respectively. In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance. In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine. As of January 2018, Otsuka's pipeline indicates it is in Phase III clinical trials. (en)
dbo:casNumber	924012-43-1
dbo:fdaUniiCode	D2A6T4UH9C
dbo:kegg	D10697
dbo:pubchem	16095349
dbo:thumbnail	wiki-commons:Special:FilePath/Centanafadine.svg?width=300
dbo:wikiPageExternalLink	http://www.neurovance.com/wp-content/uploads/2014/05/Press_Release_Neurovance_EB-1020_Data_050714.pdf%7Caccess-date=14 http://adisinsight.springer.com/drugs/800035830
dbo:wikiPageID	48554101 (xsd:integer)
dbo:wikiPageLength	4974 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1120769856 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Euthymics_Bioscience dbr:Bicifadine dbr:Attention-deficit_hyperactivity_disorder dbr:DOV_Pharmaceutical dbc:Cyclopropanes dbc:Nitrogen_heterocycles dbc:Stimulants dbr:Amitifadine dbr:DOV-216,303 dbr:Dasotraline dbr:Drug_development dbr:Norepinephrine dbc:2-Naphthyl_compounds dbc:Serotonin–norepinephrine–dopamine_reuptake_inhibitors dbr:International_Nonproprietary_Name dbr:Tesofensine dbr:Dopamine dbr:Serotonin dbr:Reuptake dbr:Serotonin-norepinephrine-dopamine_reuptake_inhibitor
dbp:c	15 (xsd:integer)
dbp:casNumber	924012 (xsd:integer)
dbp:chemspiderid	17253639 (xsd:integer)
dbp:h	15 (xsd:integer)
dbp:iupacName	-1 (xsd:integer)
dbp:kegg	D10697 (en)
dbp:legalUs	Investigational New Drug (en)
dbp:n	1 (xsd:integer)
dbp:pubchem	16095349 (xsd:integer)
dbp:smiles	C1=C[C@@]34C[C@@H]3CNC4 (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	HKHCSWPSUSWGLI-CABCVRRESA-N (en)
dbp:unii	D2A6T4UH9C (en)
dbp:width	180 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Nervous-system-drug-stub dbt:Reflist dbt:Short_description dbt:Abbrlink dbt:Fdacite dbt:Keggcite dbt:Monoamine_reuptake_inhibitors
dcterms:subject	dbc:Cyclopropanes dbc:Nitrogen_heterocycles dbc:Stimulants dbc:2-Naphthyl_compounds dbc:Serotonin–norepinephrine–dopamine_reuptake_inhibitors
gold:hypernym	dbr:Inhibitor
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Centanafadine (INN) (former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical. It was developed as a treatment for attention-deficit hyperactivity disorder (ADHD) and inhibits the reuptake of norepinephrine, dopamine, and serotonin with a ratio of 1:6:14, respectively. In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance. In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine. As of January 2018, Otsuka's pipeline indicates it is in Phase III clinical trials. (en)
rdfs:label	Centanafadine (en)
owl:sameAs	yago-res:Centanafadine wikidata:Centanafadine https://global.dbpedia.org/id/2YwrE
prov:wasDerivedFrom	wikipedia-en:Centanafadine?oldid=1120769856&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Centanafadine.svg
foaf:isPrimaryTopicOf	wikipedia-en:Centanafadine
is dbo:wikiPageRedirects of	dbr:EB-1020 dbr:EB1020 dbr:EB_1020
is dbo:wikiPageWikiLink of	dbr:List_of_investigational_attention_deficit_hyperactivity_disorder_drugs dbr:Amitifadine dbr:Dasotraline dbr:Otsuka_Pharmaceutical dbr:C15H15N dbr:Serotonin–norepinephrine–dopamine_reuptake_inhibitor dbr:EB-1020 dbr:EB1020 dbr:EB_1020
is foaf:primaryTopic of	wikipedia-en:Centanafadine